Post-earnings recap
Reported
Tue, Nov 12, 2024
EPS actual
$-0.28
EPS est.
$-0.33
EPS surprise
+14.63%
1-day move
-3.89%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Terns Pharmaceutical reported a wider-than-expected loss per share, which led to a 3.89% decline in stock price. Investors may be concerned about the lack of revenue details and the absence of forward guidance. The management's cautious tone suggests that the company is facing challenges that could impact its performance in the near term.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | +14.63% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding market conditions. They highlighted their commitment to navigating challenges while focusing on future growth.
Management noted ongoing challenges in the market.
They emphasized a focus on long-term strategy despite current setbacks.